Premium
The evolution of dasatinib dosage over the years and its relevance to other anticancer medications
Author(s) -
Schiffer Charles A.
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31516
Subject(s) - dasatinib , medicine , myeloid leukemia , pharmacology , oncology , schedule , imatinib , computer science , operating system
A lower dose of 50 mg of dasatinib is effective when used as the initial treatment of patients with chronic‐phase chronic myeloid leukemia. This observation has implications for dose and schedule considerations for other anticancer drugs. See also pages 2740‐7.